Inactief instrument

Andere talen STADA Arzneimittel CBOE EUROPE EQUITIES

Aandelen

0OM4

DE0007251803

slotkoers CBOE EUROPE EQUITIES Andere beurzen
- ^EUR	-

2023

Alvotech, Stada krijgen steun van EU-panel voor Stelara Biosimilar

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy	30/05
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	29/05
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US	10/05
Arzneikonzern Stada wächst - Finanzinvestoren prüfen Ausstieg	14/03
Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue	04/03
Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar	10/11
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy	03-10-23
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU	28-09-23
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet	15-08-23
STADA Arzneimittel AG / STADA mit hervorragendem Halbjahresergebnis und ...	15-08-23
STADA and Xbrane weigh options for ranibizumab biosimilar candidate	25-07-23
STADA Arzneimittel AG / STADA baut Consumer-Healthcare-Portfolio in ...	12-07-23
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate	21-06-23
STADA AND XBRANE LAUNCH XIMLUCI AS RANIBIZUMAB BIOSIMILAR IN GERMANY	26-05-23
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany	26-05-23
STADA AND XBRANE SUPPLY XIMLUCI IN ENGLAND UNDER NHS CONTRACT	26-04-23
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract	25-04-23
STADA and Xbrane launch ranibizumab to support patient access in Europe	03-04-23
STADA Arzneimittel AG / STADAs nachhaltiger Wachstumskurs führt 2022 zu ...	06-03-23
AFR: STADA Arzneimittel AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG	23-02-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen STADA Arzneimittel CBOE EUROPE EQUITIES

Aandelen

0OM4

DE0007251803

Andere talen

Filters